Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
PMPaul M. RidkerEDEleanor DanielsonFAFrancisco Antônio Helfenstein FonsecaJGJacques GenestAMAntonio M. Gotto
Brigham and Women's Hospital · Harvard University · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,019
total citations
- FWCI
- 125.46
- Percentile
- 100%
- References
- 29
Citations per year
Authors
14- PMPaul M. RidkerCorresponding
Brigham and Women's Hospital, Harvard University
- EDEleanor Danielson
Brigham and Women's Hospital, Harvard University
- FAFrancisco Antônio Helfenstein Fonseca
Universidade Federal de São Paulo
- JGJacques Genest
McGill University Health Centre
- AMAntonio M. Gotto
Cornell University
Topics & keywords
Topics
Keywords
- Rosuvastatin
- Medicine
- Internal medicine
- Rosuvastatin Calcium
- Cholesterol
- Reduction (mathematics)
- Ldl cholesterol
- Cardiology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.